CS MEDICA defers the Q4 2022/2023 quarterly report until Wednesday 22. November 2023

CS MEDICA is postponing the Year-end-Report Q4 2022/2023 until Wednesday 22. November 2023.

CS MEDICA A/S ("CS MEDICA" or the "Company"), a MedTech company that focuses on treating pain, autoimmune diseases, and stress-related disorders with therapeutic CBD/cannabinoids, is postponing its quarterly report Q4 2022/2023 to Wednesday, 22 November 2023.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and operating within the pharmaceutical industry. The company combines science and nature with the purpose of creating over-the-counter treatments to fight autoimmune and stress-related diseases, built upon our knowledge of the endocannabinoid system, patients' needs, and our experience in the pharmaceutical industry. We do so by pioneering scientific breakthroughs, expanding access to our treatments, understanding patients globally, and working to prevent the pain caused by the diseases we treat.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

Tags: